GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (BSP:REGN34) » Definitions » Cyclically Adjusted Price-to-FCF

Regeneron Pharmaceuticals (BSP:REGN34) Cyclically Adjusted Price-to-FCF : 42.02 (As of May. 17, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Regeneron Pharmaceuticals Cyclically Adjusted Price-to-FCF?

As of today (2024-05-17), Regeneron Pharmaceuticals's current share price is R$83.20. Regeneron Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was R$1.98. Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is 42.02.

The historical rank and industry rank for Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BSP:REGN34' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 32.1   Med: 70.87   Max: 1182.8
Current: 40.53

During the past years, Regeneron Pharmaceuticals's highest Cyclically Adjusted Price-to-FCF was 1182.80. The lowest was 32.10. And the median was 70.87.

BSP:REGN34's Cyclically Adjusted Price-to-FCF is ranked better than
61.54% of 104 companies
in the Biotechnology industry
Industry Median: 55.165 vs BSP:REGN34: 40.53

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted free cash flow per share data for the three months ended in Mar. 2024 was R$0.974. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is R$1.98 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regeneron Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.97 59.67 42.70 38.07 39.41

Regeneron Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.77 34.15 37.47 39.41 40.30

Competitive Comparison of Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Regeneron Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=83.20/1.98
=42.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Regeneron Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.974/131.7762*131.7762
=0.974

Current CPI (Mar. 2024) = 131.7762.

Regeneron Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.088 100.560 0.115
201409 0.028 100.428 0.037
201412 0.031 99.070 0.041
201503 -0.099 99.621 -0.131
201506 0.008 100.684 0.010
201509 0.419 100.392 0.550
201512 0.058 99.792 0.077
201603 -0.032 100.470 -0.042
201606 0.128 101.688 0.166
201609 0.248 101.861 0.321
201612 0.116 101.863 0.150
201703 0.138 102.862 0.177
201706 -0.040 103.349 -0.051
201709 0.158 104.136 0.200
201712 0.218 104.011 0.276
201803 0.257 105.290 0.322
201806 0.155 106.317 0.192
201809 0.206 106.507 0.255
201812 0.363 105.998 0.451
201903 0.456 107.251 0.560
201906 0.053 108.070 0.065
201909 0.262 108.329 0.319
201912 0.388 108.420 0.472
202003 0.374 108.902 0.453
202006 0.597 108.767 0.723
202009 -0.322 109.815 -0.386
202012 0.818 109.897 0.981
202103 0.470 111.754 0.554
202106 0.362 114.631 0.416
202109 2.534 115.734 2.885
202112 1.843 117.630 2.065
202203 1.437 121.301 1.561
202206 0.303 125.017 0.319
202209 -0.341 125.227 -0.359
202212 1.125 125.222 1.184
202303 0.829 127.348 0.858
202306 0.631 128.729 0.646
202309 0.664 129.860 0.674
202312 0.557 129.419 0.567
202403 0.974 131.776 0.974

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regeneron Pharmaceuticals  (BSP:REGN34) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Regeneron Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals (BSP:REGN34) Business Description

Traded in Other Exchanges
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Regeneron Pharmaceuticals (BSP:REGN34) Headlines

No Headlines